Company: INGN
Filing Date: 2025-03-27
Form Type: DEF 14A
Source: 0000950170-25-045737
Chunk: 42

Company: Inogen Inc
Filing Date: 2025-03-27
Form: DEF 14A
Chunk 42
---
 value in recruiting and retaining highly qualified technical and other key personnel who are in great demand, as well as rewarding and encouraging current employees and other service providers. Finally, our Board and management believe that the ability to grant equity awards will be important to our future success by helping us to accomplish these objectives.

If our stockholders approve the Amended and Restated Plan, we currently anticipate that the shares available under the Amended and Restated Plan will be sufficient to meet our expected needs through calendar year 2025. We anticipate that we will be requesting additional shares under the Amended and Restated Plan at our 2026 annual meeting of stockholders. However, future circumstances and business needs may dictate a different result. In determining the number of shares to be reserved for issuance under the Amended and Restated Plan, our Compensation Committee and our Board also considered the following:

Remaining Competitive by Attracting/Retaining Talent . As discussed above, our Compensation Committee and our Board considered the importance of an adequate pool of shares to attract, retain and reward our high-performing employees, especially since we compete with many life sciences companies for a limited pool of talent.

<div align='center'>-27-</div>

Historical Grant Practices . Our Compensation Committee and our Board considered the historical amounts of equity awards that we have granted in the past three years. In fiscal years 2024, 2023, and 2022, we granted equity awards representing a total of 4,248,900 shares (assuming maximum performance in the case of performance-based awards). This figure reflects the grants that we have made according to our historical practices of a broad-based plan for executives and non-executives, but changes in our stock price may impact the number of shares covered by awards that we grant in the future. Additionally, our Board considered the underperformance and extensive turnover of our executive management team in 2023 and 2024.

Forecasted Grants . As discussed above, our Compensation Committee and our Board anticipate, based on projected share utilization, that the proposed share reserve will be sufficient for our equity award usage through calendar year 2025. In determining the projected share utilization, our Compensation Committee and our Board considered a forecast that included the following factors as of March 3, 2025 (the date of initial action by our Board to approve the Amended and Restated Plan): (i) the approximately 995,635 unissued shares remaining under the 2023 Plan as of the date of the initial action by our Board to approve the